All stock lists
Opko Health, Inc. (NASDAQ:OPK)
US · Delayed Price · Currency is USD
Also listed: 0KCS.L, OPK.TAHealthcare · Medical - Diagnostics & Research
1.75-0.02 (-1.13%)
Market cap
$1.31B
Insider Score
Health Score
Analyst consensus
Listed since
Nov 2, 1995
Website
Insider Score
––Not scored
OPK Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
OPK analyst forecast
OPK analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
OPK 12-month price target
No published price targets in the last 12 months.
OPK ratings mix, last 12 months
Buy Hold Sell
Best analysts covering OPK
- Barrington Research30%success rate · -4.1% avg return · 10 calls
- Piper Sandler20%success rate · -10.2% avg return · 5 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
OPK analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-10-16 |
| — | Barrington Research | Outperform | — | — | Upgraded | 2026-10-16 |
| — | Barrington Research | Market Perform | — | — | Downgraded | 2026-04-29 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-03-02 |
| — | Jefferies | Hold | — | — | Downgraded | 2025-10-31 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-10-30 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-05-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-19 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-03-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-03 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-02-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-08 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-11-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-26 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-09-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-09-17 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-09-17 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-08-08 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-07-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-04-03 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-04-01 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-04-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-02-28 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-02-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-07 |
| — | Barrington Research | Outperform | — | — | Upgraded | 2023-06-29 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-02-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-12-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-08-05 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2022-05-10 |
| — | Barrington Research | Market Perform | — | — | Downgraded | 2022-01-24 |
| — | Ladenburg Thalmann | Buy | — | — | Reiterated | 2021-06-21 |
| — | Piper Jaffray | Overweight | — | — | Reiterated | 2019-11-25 |
| — | JP Morgan | Underweight | — | — | Downgraded | 2018-03-02 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2017-09-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2017-08-18 |
| — | Guggenheim | Buy | — | — | Reiterated | 2017-03-14 |
| — | Standpoint Research | Buy | — | — | Reiterated | 2016-12-30 |
| — | Deutsche Bank | Hold | — | — | Reiterated | 2016-06-16 |
| — | Standpoint Research | Buy | — | — | Reiterated | 2016-06-03 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2016-03-31 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2015-10-16 |
| — | Laidlaw & Co. | Buy | — | — | Reiterated | 2015-08-12 |
| — | Oppenheimer | Perform | — | — | Downgraded | 2015-03-03 |
| — | Jefferies | Buy | — | — | Reiterated | 2014-08-13 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2014-05-12 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2014-03-14 |
| — | Jefferies | Buy | — | — | Reiterated | 2013-03-20 |
| — | Jefferies | Buy | — | — | Reiterated | 2013-03-19 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2013-01-29 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2012-10-22 |
OPK earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | -0.07 | -0.04 | $139.8M | $148.5M |
| 2026-04-28 | -0.07 | -0.07 | $130.5M | $124.2M |
| 2026-07-27 | -0.08 | -0.01 | $131.2M | $163.5M |
| 2026-11-04 | -0.07 | -0.05 | $136.6M | $65.4M |
| 2027-02-25Upcoming | -0.08 | — | $133.2M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.